Key facts
- This page summarizes Peter Rahmer's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 31 Jul 2023, 16:52.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Additional SEC filing notes
Footnote F1
Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Footnote F2
Includes 284,835 shares underlying RSUs.
SEC remarks
Title: Chief Corporate Development Officer